To: Endra Life Sciences Inc. Board,

Based on previously published float and declared shares, we represented the majority of shareholders of ENDRA Life Sciences Inc and we demand you to take steps to prevent the manipulation of NDRA's stock price as listed in Nasdaq.

We insist to be informed about any buyout offers and to be familiarized with any offers, requests, or discussions regarding acquisition, partnerships, or licensing partnerships that come through the board room. You may email your updates to us at NDRA@activistforce.com.

We also have serious concerns about the Series B Warrants you've recently executed and demand full transparency about the issuance of shares as they relate to those warrants.

We would like you to protect our assets including the 81 global patents, the $6.4M in cash reported in your last quarterly report, and the technology behind the TAEUS thermo-acoustic imaging system that you have developed. Also, given the recent 103.36M volume in shares traded in a single day, representing 7,436% of the published free float, we feel strongly that you should use $250K of the $6.4M in reported cash to immediately engage in an NDRA stock buy back program so long as NDRA's stock price remains below $1.00. Furthermore, repurchased shares under this program should be earmarked Treasury Stock which may be reissued above $10.00. Not only would this shore up cheap shares for the company, it would allow for greater future growth. We also want you to explore licensing and salesforce relationships to generate immediate revenue. We strongly believe ENDRA is capable of self-funding with revenue and profits.

NDRA is a publicly traded company that deserves to be led with top quality leadership and stewardship. We implore you to act accordingly.

If we cannot get an appropriate response, we may seek to hold a vote to restructure the board with one that is effective, responsible, and most importantly; responsive.

Signed, Investor List